Myotonic Dystrophy Type 1
A genetic disorder causing progressive muscle wasting and inability to relax muscles after use, along with cataracts, heart rhythm problems, and endocrine issues.
Emergency Management: Complete heart block requiring emergent transvenous pacing. Acute respiratory failure triggered by a minor upper respiratory infection.
Myotonic Dystrophy Type 1 (DM1) is an autosomal dominant, multisystem disorder characterized by progressive skeletal muscle weakness, wasting, and myotonia (delayed relaxation of voluntary muscle). Beyond skeletal muscle, it heavily involves cardiac muscle, the ocular lens (cataracts), the endocrine system, and the central nervous system.
Detailed Overview
DM1 is the most common adult-onset muscular dystrophy. It is caused by an expanded CTG trinucleotide repeat in the 3' untranslated region of the DMPK gene. This expanded RNA acts toxically, sequestering RNA-splicing proteins (like MBNL1) and leading to widespread aberrant alternative splicing in multiple tissues. The disease exhibits anticipation, meaning subsequent generations often have larger expansions, earlier onset, and more severe symptoms. Cardiac conduction defects are a leading cause of sudden death in these patients.
Epidemiology & Demographics
Prevalence is approximately 1 in 8,000 to 1 in 20,000 individuals worldwide. It is the most common adult muscular dystrophy. Affects both sexes equally.
Etiological Mechanism
Autosomal dominant inheritance of a CTG repeat expansion (>50 repeats) in the DMPK (Dystrophia Myotonica Protein Kinase) gene located on chromosome 19q13.3.
Primary Causes
The expanded CTG repeats are transcribed into mutant mRNA that accumulates in the nucleus. This mutant RNA traps essential RNA-binding proteins (Muscleblind-like 1, MBNL1) and upregulates others (CELF1). This dysregulation causes massive failure in the proper alternative splicing of dozens of genes (e.g., CLCN1 for myotonia, INSR for insulin resistance, cTNNT2 for cardiac issues).
Splicing misregulation of the CLCN1 (muscle chloride channel) gene leads to loss of chloride conductance, causing membrane hyperexcitability and myotonia. Mis-splicing in cardiac tissue leads to fibrosis of the His-Purkinje system, causing AV blocks and arrhythmias. Muscle fiber degeneration and fibrous tissue replacement cause progressive weakness. Central nervous system involvement leads to daytime sleepiness, apathy, and cognitive impairment.
Diagnostic Criteria & Guidelines
Clinical phenotype (myotonia, distal weakness, cataracts) confirmed by molecular genetic testing showing >50 CTG repeats in the DMPK gene.
Multidisciplinary management. Myotonia: Mexiletine 150 mg PO BID (requires baseline normal ECG as it is proarrhythmic). Cardiac: Annual ECG and Holter monitor; pacemaker/ICD placement is life-saving for severe conduction blocks. Respiratory: BiPAP for nocturnal hypoventilation.
Second-Line & Adjunctive Therapy
Excessive Daytime Sleepiness: Modafinil 100-200 mg/day or Methylphenidate. Dysphagia/Nutrition: Swallowing therapy and eventual PEG tube placement for severe aspiration risk.
Surgical & Procedural Management
Cataract extraction surgery is frequently required at an unusually early age (30s-40s). Orthopedic interventions (e.g., ankle-foot orthoses) for foot drop.
Patient Counseling & Advice
Extensive genetic counseling is required. Explain the concept of 'anticipation'—if they have children, the disease may present much earlier and more severely. Emphasize the critical importance of annual cardiology visits, as heart rhythm problems are silent but deadly.
Follow-Up & Monitoring Schedule
Annual ECG/Holter monitor. Annual forced vital capacity (FVC) measurement. Annual slit-lamp eye exam. Regular screening for diabetes and thyroid dysfunction.
Preventive Strategies
Preimplantation genetic testing (PGT) during IVF for families with known DMPK mutations to prevent transmission.
Highly variable based on repeat length. Classic adult-onset patients typically become wheelchair-dependent by their 50s and have a reduced life expectancy (median survival ~50-60 years), most commonly dying from respiratory failure or sudden cardiac death.